Vildagliptin action on some adipocytokine levels in type 2 diabetic patients

A 12-month, placebo-controlled study

Giuseppe Derosa, Pietro D. Ragonesi, Anna Carbone, Elena Fogari, Angela D'Angelo, Arrigo Fg Cicero, Pamela Maffioli

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: To evaluate the action of vildagliptin + metformin on some adipocytokine levels, glycemic control, and β-cell function in type 2 diabetic patients. Research design and Methods: A total of 171 patients with poor glycemic control were instructed to add after a 8 ± 2 month-run-in period with metformin, vildagliptin 50 mg twice a day or placebo for 12 months. Main outcome measures: We evaluated at 3, 6, 9, and 12 months, the body mass index (BMI), glycemic control, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment β-cell function index (HOMA-β), fasting plasma proinsulin (FPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, resistin, retinol-binding protein-4 (RBP-4), chemerin, and tumor necrosis factor-α (TNF-α). Patients also underwent a combined euglycemic hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. Results: After 12 months of vildagliptin + metformin, we observed a better decrease of body weight, glycemic control, HOMA-IR, and glucagon, and a better increase of HOMA-β, and of all the measures of β-cell function, compared to placebo + metformin. Vildagliptin + metformin also decreased resistin, RBP-4, and chemerin better. Conclusion: Vildagliptin seems to have a positive action on some adipocytokines related to inflammation.

Original languageEnglish
Pages (from-to)2581-2591
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume13
Issue number18
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Adipokines
compound A 12
Metformin
Placebos
Resistin
Insulin Resistance
Proinsulin
Retinol-Binding Proteins
Fasting
Homeostasis
Insulin
Glucagon
C-Peptide
Arginine
Body Mass Index
Research Design
Tumor Necrosis Factor-alpha
Body Weight
Outcome Assessment (Health Care)
vildagliptin

Keywords

  • Chemerin
  • Metformin
  • RBP-4
  • Resistin
  • TNF-α, vildagliptin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Vildagliptin action on some adipocytokine levels in type 2 diabetic patients : A 12-month, placebo-controlled study. / Derosa, Giuseppe; Ragonesi, Pietro D.; Carbone, Anna; Fogari, Elena; D'Angelo, Angela; Cicero, Arrigo Fg; Maffioli, Pamela.

In: Expert Opinion on Pharmacotherapy, Vol. 13, No. 18, 12.2012, p. 2581-2591.

Research output: Contribution to journalArticle

@article{2934b5fc97d74b7a977d6520b278ac6a,
title = "Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: A 12-month, placebo-controlled study",
abstract = "Objective: To evaluate the action of vildagliptin + metformin on some adipocytokine levels, glycemic control, and β-cell function in type 2 diabetic patients. Research design and Methods: A total of 171 patients with poor glycemic control were instructed to add after a 8 ± 2 month-run-in period with metformin, vildagliptin 50 mg twice a day or placebo for 12 months. Main outcome measures: We evaluated at 3, 6, 9, and 12 months, the body mass index (BMI), glycemic control, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment β-cell function index (HOMA-β), fasting plasma proinsulin (FPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, resistin, retinol-binding protein-4 (RBP-4), chemerin, and tumor necrosis factor-α (TNF-α). Patients also underwent a combined euglycemic hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. Results: After 12 months of vildagliptin + metformin, we observed a better decrease of body weight, glycemic control, HOMA-IR, and glucagon, and a better increase of HOMA-β, and of all the measures of β-cell function, compared to placebo + metformin. Vildagliptin + metformin also decreased resistin, RBP-4, and chemerin better. Conclusion: Vildagliptin seems to have a positive action on some adipocytokines related to inflammation.",
keywords = "Chemerin, Metformin, RBP-4, Resistin, TNF-α, vildagliptin",
author = "Giuseppe Derosa and Ragonesi, {Pietro D.} and Anna Carbone and Elena Fogari and Angela D'Angelo and Cicero, {Arrigo Fg} and Pamela Maffioli",
year = "2012",
month = "12",
doi = "10.1517/14656566.2012.734499",
language = "English",
volume = "13",
pages = "2581--2591",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "18",

}

TY - JOUR

T1 - Vildagliptin action on some adipocytokine levels in type 2 diabetic patients

T2 - A 12-month, placebo-controlled study

AU - Derosa, Giuseppe

AU - Ragonesi, Pietro D.

AU - Carbone, Anna

AU - Fogari, Elena

AU - D'Angelo, Angela

AU - Cicero, Arrigo Fg

AU - Maffioli, Pamela

PY - 2012/12

Y1 - 2012/12

N2 - Objective: To evaluate the action of vildagliptin + metformin on some adipocytokine levels, glycemic control, and β-cell function in type 2 diabetic patients. Research design and Methods: A total of 171 patients with poor glycemic control were instructed to add after a 8 ± 2 month-run-in period with metformin, vildagliptin 50 mg twice a day or placebo for 12 months. Main outcome measures: We evaluated at 3, 6, 9, and 12 months, the body mass index (BMI), glycemic control, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment β-cell function index (HOMA-β), fasting plasma proinsulin (FPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, resistin, retinol-binding protein-4 (RBP-4), chemerin, and tumor necrosis factor-α (TNF-α). Patients also underwent a combined euglycemic hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. Results: After 12 months of vildagliptin + metformin, we observed a better decrease of body weight, glycemic control, HOMA-IR, and glucagon, and a better increase of HOMA-β, and of all the measures of β-cell function, compared to placebo + metformin. Vildagliptin + metformin also decreased resistin, RBP-4, and chemerin better. Conclusion: Vildagliptin seems to have a positive action on some adipocytokines related to inflammation.

AB - Objective: To evaluate the action of vildagliptin + metformin on some adipocytokine levels, glycemic control, and β-cell function in type 2 diabetic patients. Research design and Methods: A total of 171 patients with poor glycemic control were instructed to add after a 8 ± 2 month-run-in period with metformin, vildagliptin 50 mg twice a day or placebo for 12 months. Main outcome measures: We evaluated at 3, 6, 9, and 12 months, the body mass index (BMI), glycemic control, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment β-cell function index (HOMA-β), fasting plasma proinsulin (FPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), C-peptide, glucagon, resistin, retinol-binding protein-4 (RBP-4), chemerin, and tumor necrosis factor-α (TNF-α). Patients also underwent a combined euglycemic hyperinsulinemic and hyperglycemic clamp, with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. Results: After 12 months of vildagliptin + metformin, we observed a better decrease of body weight, glycemic control, HOMA-IR, and glucagon, and a better increase of HOMA-β, and of all the measures of β-cell function, compared to placebo + metformin. Vildagliptin + metformin also decreased resistin, RBP-4, and chemerin better. Conclusion: Vildagliptin seems to have a positive action on some adipocytokines related to inflammation.

KW - Chemerin

KW - Metformin

KW - RBP-4

KW - Resistin

KW - TNF-α, vildagliptin

UR - http://www.scopus.com/inward/record.url?scp=84870201257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870201257&partnerID=8YFLogxK

U2 - 10.1517/14656566.2012.734499

DO - 10.1517/14656566.2012.734499

M3 - Article

VL - 13

SP - 2581

EP - 2591

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 18

ER -